Lung Cancer Screening Market Report

Global Lung Cancer Screening Market Size

The global lung cancer screening market size was valued at USD 3.18 billion in 2025 and is estimated to reach USD 6.95 billion by 2034 from USD 3.47 billion in 2026, registering a CAGR of 9.08% from 2026 to 2034

Lung cancer is the leading cause of cancer-related deaths worldwide, primarily associated with smoking, although it can also occur in non-smokers. The risk of developing lung cancer is closely linked to the duration and quantity of cigarette smoking. However, quitting smoking, even after long-term use, can substantially reduce the likelihood of developing lung cancer. It typically originates in the airways (bronchi or bronchioles) or the tiny air sacs (alveoli) of the lungs. It results from uncontrolled cell division, where cells multiply beyond their normal function. Genetic mutations can cause these cells to continue multiplying uncontrollably, forming masses or tumors that interfere with the proper functioning of organs. Treatment options for lung cancer include surgery, chemotherapy, immunotherapy, radiation, and targeted drugs. High-risk individuals are recommended to undergo regular screenings.

The diagnosis of lung cancer often involves multiple steps, such as blood tests, chest X-rays, imaging tests (e.g., CT scans), and biopsies. Additional tests may include PET/CT scans to assess the spread of cancer and analysis of cancerous tissue samples from biopsies to determine the most effective treatment approach. In recent years, advancements in treatment options have contributed to a significant decline in lung cancer-related deaths.

MARKET DRIVERS

The growing number of research and development activities, government initiatives towards innovation investments and lung cancer diagnosis and screening tests primarily drive the growth of the lung cancer screening market. For instance, according to the American Society of Clinical Oncology, the number of lung cancer diagnoses in the U.S. is projected to reach 238,340 in 2023, with an annual loss of approximately 127,070 lives. The National Cancer Institute (NCI) is also funding research to advance the prevention, detection, and treatment of lung cancer. Government initiatives and awareness programs, such as the Assam Cancer Care Foundation's campaign on lung cancer are further contributing to raising awareness about the risks of smoking and tobacco use.

The growing prevalence of lung cancer further boosts the growth of the lung cancer screening market. The global burden of lung cancer is increasing due to factors like obesity, smoking and lifestyle changes. Smoking and vaping are nearly 23% of adults globally contributing to the rising incidence of lung cancer worldwide. This surge in cases underscores the need for effective screening tests and solutions, which in turn, are expected to drive market growth.

An increasing number of advancements in imaging technologies, such as low dose computed tomography (LDCT) that enable accurate and non-invasive screening, implementation of screening programs and guidelines by healthcare organizations and governments and rapid adoption of preventive healthcare practices and proactive cancer screening initiatives drive the growth of the lung cancer screening market. The growing aging population and the higher risk of lung cancer among older individuals, strong support from patient advocacy groups and organizations promoting lung cancer awareness and screening and rising availability and accessibility of screening facilities and equipment propel the market growth.

The integration of lung cancer screening into comprehensive cancer care programs, technological advancements in data analysis and image interpretation, an increasing number of collaborations between healthcare providers, researchers and industry players to improve screening protocols and outcomes and reimbursement coverage for lung cancer screening by private and public health insurance providers favor the market growth.

MARKET RESTRAINTS

The high cost of tests, lack of equipment and lack of awareness among people to perform screening primarily hamper the lung cancer screening market growth. False positive reports also pose a challenge to market growth, as research has shown a high percentage of false positive results. In March 2019, for instance, scientists from the University of Pittsburgh and the UPMC Hillman Cancer Centre discovered that 96% of persons who screen positive for lung cancer don't have a malignant tumor. Additionally, the high cost of screening makes it unaffordable for many individuals, particularly those in low-income brackets. Lack of awareness about screening in developing economies further hinders market growth. Furthermore, the scarcity of trained professionals like radiologists and laboratory practitioners in certain countries restricts the number of screening tests conducted.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Cancer Type Insights

Based on cancer type, the NSCLC segment is projected to occupy the leading share of the global market during the forecast period owing to the increasing awareness of screening in both developed and developing countries and the rising cases of NSCLC worldwide. According to the American Cancer Society, approximately 84% of all lung cancers are classified as non-small cell, while 13% are SCLC. Furthermore, the five-year survival rate for NSCLC is reported to be 24%, compared to 6% for SCLC, as stated by Cancer.Net.

On the other hand, the SCLC segment is expected to account for a considerable share of the worldwide market during the forecast period and the segmental growth is majorly driven by the rising prevalence of the disease and government and non-profit organization initiatives promoting early screening and diagnosis.

By Diagnosis Type Insights

Based on diagnosis type, the low-dose spiral CT scan segment is expected to hold the major share of the worldwide market during the forecast period due to favorable reimbursement policies for cancer screening and the increasing adoption of low-dose spiral CT scans. The rising awareness of the mortality benefits associated with low-dose spiral CT scan screening fuels the growth rate of the segment. The National Cancer Institute conducted the National Lung Screening Trial, involving 53,456 participants across the U.S., which revealed a 20% reduction in mortality through low-dose CT screening.

Consequently, the chest X-ray segment is projected to exhibit a lower CAGR in the coming years due to the increasing preference for low-dose spiral CT scans.

By End-user Insights

Based on end-user, the hospitals & clinics segment is predicted to account for the major share of the worldwide market during the forecast period owing to the rising preference of patients for hospitals as screening venues, the rise in the number of hospitals in emerging economies and the strong network of hospitals in developed countries. The growing awareness among the general population and the implementation of screening programs in healthcare facilities further contribute to segmental growth.

Furthermore, the diagnostic centers segment is expected to exhibit a faster CAGR during the forecast period and the growth of the diagnostic centers segment is majorly driven by the collaborations between healthcare providers and payers with diagnostic facilities to offer screening programs, as well as the increasing number of diagnostic centers in developed countries worldwide.

REGIONAL ANALYSIS

North America led the market in 2024 and is anticipated to account for the largest share of the worldwide market during the forecast period owing to factors such as the growing number of lung cancer cases, the robust implementation of screening programs and the increasing adoption of technologically advanced solutions.

Europe accounted for the second-largest share of the global market in 2024 and is anticipated to register a noteworthy CAGR during the forecast period. The presence of a well-established healthcare sector in European countries, the rising prevalence of lung cancer primarily attributed to an increasing smoking population, and the accessibility to advanced screening devices in healthcare facilities contribute to the European market growth. According to the European Society for Medical Oncology, smoking was responsible for approximately 85% of non-small cell lung cancer cases among the total patients in 2020.

Asia Pacific is anticipated to experience lucrative growth during the forecast period. The region draws global attention due to its high rate of smoking and tobacco consumption among the population. Increased initiatives by market players and government institutes to promote the adoption of screening devices, as well as efforts by national government agencies to establish robust frameworks for lung cancer screening, are significant drivers of market growth in the region.

Latin America is projected to hold a comparatively lower share of the global market due to factors such as limited awareness and restricted access to screening services. In the Gulf region, there is a strong focus on hospital and healthcare infrastructure development, with rising government investments to support the growth of healthcare facilities. Additionally, the entry of private players into the healthcare sector in the Middle East and Africa region contributes to favorable conditions for market growth during the forecast period.

KEY MARKET PLAYERS

Some of the companies that are playing a dominating role in the market include

• Abbott
• Illumina, Inc.
• Thermo Fisher Scientific
• QIAGEN
• Quest Diagnostics Incorporated
• NeoGenomics
• NanoString
• Myriad Genetics, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher
• Agilent Technologies, Inc.
• AstraZeneca
• Sanofi
• Janssen Pharmaceuticals, Inc.

RECENT  MARKET HAPPENINGS

• In October 2022, Quest Diagnostics announced a new chapter of the partnership with Decode Health. This partnership has aided the business in decreasing the time and expense involved in creating fresh diagnostic tests and finding new medication targets for various cancers and increased the company's global presence.
• In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases.

MARKET SEGMENTATION

This research report on the global lung cancer screening market has been segmented and sub-segmented based on the following categories.

By Cancer Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

By Diagnosis Type

• Low-Dose Spiral CT scans
• Chest X-Ray

By End-user

• Hospitals & clinics
• Diagnostic centers

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East & Africa